Cipla, Pfizer ink partnership for exclusive marketing of four brands in India

Pharmaceutical companies Pfizer India and Cipla Limited today announced a partnership where Cipla will exclusively market and distribute four key brands of Pfizer in India.

Under the agreement, Cipla now has the sole right to market, distribute and sell the cough syrup- Corex Dx and Corex LS, the non-steroidal anti-inflammatory drug (NSAID) Dolonex, the proton pump inhibitor (PPI) Neksium and the oral antibiotic Dalacin C in India, the company said in a statement.

Pfizer will continue to manufacture, source and supply these medicines to Cipla for India, it further said.


The companies did not disclose the details about the deal.

According to Achin Gupta, Global Chief Operating Officer, Cipla Ltd their distribution capabilities will support wider reach to patients who need them the most.

“At Cipla, we believe meaningful partnerships help make strong brands even stronger. This association with Pfizer aligns with our continued focus on building a formidable presence across key therapy areas and enhancing access to high quality treatments guided by our purpose of ‘Caring for Life’,” he said.

Meenakshi Nevatia, country President, Pfizer India said that the partnership will help meet the needs of millions of patients across India effectively.

“At Pfizer, expanding the reach of our medicines for patients is paramount and we are delighted to partner with Cipla to achieve this common mission…..Together, we are committed to advancing healthcare outcomes and enhancing patient lives everywhere,” she said.